# Iodine Status Has No Impact on Thyroid Function in Early Healthy Pregnancy

Authors: F. Brucker-Davis; P. Ferrari; J. Gal; F. Berthier; P. Fenichel; S. Hieronimus
Journal: Journal of Thyroid Research
 (2012)

---

## Abstract

Aim. To assess the impact of iodine status in early pregnancy on thyroid function. Methods. Women >18 years old seen at their first prenatal consult before 12 weeks of amenorrhea and without personal thyroid history were proposed thyroid screening and were eligible if they had strictly normal thyroid tests (fT4 > 10th percentile, TSH < 2.5 mUI/L, negative anti-TPO antibodies). Evaluation included thyroid ultrasound, extensive thyroid tests, and ioduria (UIE). Results. 110 women (27.5 y, 8 weeks of amenorrhea, smoking status: 28% current smokers) were enrolled. Results are expressed as medians. UIE was 116 μg/L. 66.3% of women had iodine deficiency (ID) defined as UIE < 150. FT4 was 14.35 pmol/L; TSH 1.18 mUI/L; fT3 5 pmol/L; thyroglobulin 17.4 ng/mL; rT3 0.27 ng/mL; thyroid volume: 9.4 ml. UIE did not correlate with any thyroid tests, but correlated negatively with thyroid volume. UIE and all thyroid tests, except fT3, correlated strongly with βhCG. Smoking correlated with higher thyroid volume and thyroglobulin and with lower rT3. Conclusions. In pregnant women selected for normal thyroid function, mild ID is present in 66% during the 1st trimester. The absence of correlation between UIE and thyroid tests at that stage contrasts with the impact of βhCG and, to a lesser degree, maternal smoking.


---

## Body

## 1. Introduction

Mild iodine deficiency (ID) is still common in western Europe, despite government programs aiming at its eradication, usually based on salt iodination. Diagnosis of ID still rests on spot ioduria (UIE) at the population level, though this tool is imperfect [1]. We have previously shown in a cross-sectional study that the prevalence of ID in pregnant women of our area was present during the 3d trimester in more than three-quarter of cases [2].While severe ID is associated with dramatic impairment of neurocognitive development of the offspring, the deleterious developmental impact of mild to moderate ID is less documented [3, 4]. It could be mediated by fetal ID per se or via maternal hypothyroxinemia or hypothyroidism that may develop in predisposed women during pregnancy [5–7]. The changes of thyroid economy throughout pregnancy include a drop in fT4 after an early phase of thyroid stimulation [8]. However, the definition of maternal hypothyroxinemia is debated [5, 9]. The benefit of iodine supplementation is documented for women selected for thyroid hyperstimulation in early pregnancy and their offspring, based on fetal thyroglobulin (Tg) [10], or in case of severe to moderate ID based on neurodevelopmental evaluation [3, 11, 12]. However, there is no definitive evidence of a benefit both in terms of maternal thyroid function and of neurocognitive development of her offspring in healthy pregnant women with normal thyroid function at the beginning of pregnancy [13].We report here results assessing the impact of iodine status on thyroid function during the first trimester of pregnancy in healthy women.


## 2. Patients and Methods

### 2.1. Patients

In order to select pregnant women with normal thyroid tests, we proposed a thyroid screen to all women who age > 18 years, without personal history of thyroid disease consulting at the obstetric clinic of our hospital before 12 weeks of amenorrhea (WA) with a singleton pregnancy between July 2007 and July 2008. The screening evaluation included free T4, TSH, and antithyroperoxidase (TPO) antibodies. For this study, we specifically recruited women who were not taking iodine supplementation. A spot urine sample was also collected to allow UIE measurement in case of participation to the study. We included 110 TPO-negative women with strict criteria of normal thyroid tests who agreed to participate and signed a consent form. Ranges for normal thyroid tests in our laboratory for the first trimester are (2.5–97.5 percentile of TPO negative women) fT4: 11.47–19.3 pmol/L; TSH: 0.053–3.23 mUL/L. We selected women with fT4 > 10th percentile (12 pmol/L) and TSH < 2.5 mUL/mL, as that threshold is currently recommended for pregnant women [14].Maternal smoking was assessed qualitatively by self-reported statement: never smoked, current smokers, and former smokers (regroup women who quit smoking before pregnancy or when diagnosed as pregnant).Thyroid ultrasound was performed by two of us (F. Barker Davis and S. Hieronimus) who concerted and agreed before the study about thyroid volume measurement criteria using an En Visor scanner (Philips Medical System) equipped with a commercially available from 5 to 12 MHz linear transducer (50 mm length). Volume was calculated in mL for each lobe according to the formula 0.52 × height × width × thickness in centimeters. Total thyroid volume was the sum of each lobe’s volume, the isthmus was not taken into account in volume calculation.


### 2.2. Assays

Spot UIE was measured by mass spectrometry ICP/MS (Pasteur-Cerba Laboratory, Cergy Pontoise, France, detection threshold 15μg/L; intra- and interseries CV < 10%). Free T4 (fT4), free T3 (fT3), total T4 (TT4), TSH, βhCG, and anti-TPO and anti-Tg antibodies were measured by chemiluminescence (ADVIA Centaur, Siemens Healthcare Diagnostics, France). Tg was measured by immunoradiometric assay (Thyroglobulin IRMA, Cis bio International, Gif sur Yvette, France). Thyroxin binding globulin (TBG) and reverse T3 (rT3) were measured by radio-immunoassay (RIA): RIA-gnost TBG (Cis bio International, Gif sur Yvette, France) and RIA rT3 (Pasteur Cerba Laboratory, Cergy Pontoise, France). Reference ranges outside pregnancy, intra- and intercoefficients of variation were as the following: fT4 9–23 pmol/L (intra-assay coefficient of variation (CV) 2.31%; interassay CV 1.95%); fT3 3–7 pmol/L (intra-assay CV 2.35); TT4 during pregnancy 82.6–138 nmol/L (intra-assay CV 1.77%; interassay CV 2.9%); TSH 0.1–4 mUI/L (intra-assay CV 2.67%; interassay CV 3.97%); βhCG < 10 UI/L (intra-assay CV 2.8%; interassay CV 4.3%); TPO antibodies < 100 UI/mL (intra-assay CV 4.1%, interassay CV 8.0%); Tg antibodies < 60 UI/mL (intra-assay CV 5.5%; interassay CV 1.8%); Tg 5–50 ng/mL (intra-assay CV 2.4%; interassay CV 4.5%); rT3 0.14–0.54 nmol/L (intra-assay CV 8.54% interassay CV 6.21%); reference range for TBG for the first trimester 20.5±4.8 μg/mL (interassay CV 4.4%).


### 2.3. Statistics

Quantitative variables are expressed as means and standard deviation, medians, and range. Qualitative variables are expressed as counts and percentages. Student’st test or Mann-Whitney’s U test were used to compare continuous variables. Chi-2 test or Fisher’s exact test were used for categorical variables. The correlations between variables were determined using the Pearson’s test or Spearman’s rank test. The nonparametric Kruskal-Wallis test was used to examine associations between maternal smoking and thyroid function tests.Statistical analyses were performed using the software SAS version 9.1. Values were considered significant whenP<0.05. All tests were two-sided.


## 2.1. Patients

In order to select pregnant women with normal thyroid tests, we proposed a thyroid screen to all women who age > 18 years, without personal history of thyroid disease consulting at the obstetric clinic of our hospital before 12 weeks of amenorrhea (WA) with a singleton pregnancy between July 2007 and July 2008. The screening evaluation included free T4, TSH, and antithyroperoxidase (TPO) antibodies. For this study, we specifically recruited women who were not taking iodine supplementation. A spot urine sample was also collected to allow UIE measurement in case of participation to the study. We included 110 TPO-negative women with strict criteria of normal thyroid tests who agreed to participate and signed a consent form. Ranges for normal thyroid tests in our laboratory for the first trimester are (2.5–97.5 percentile of TPO negative women) fT4: 11.47–19.3 pmol/L; TSH: 0.053–3.23 mUL/L. We selected women with fT4 > 10th percentile (12 pmol/L) and TSH < 2.5 mUL/mL, as that threshold is currently recommended for pregnant women [14].Maternal smoking was assessed qualitatively by self-reported statement: never smoked, current smokers, and former smokers (regroup women who quit smoking before pregnancy or when diagnosed as pregnant).Thyroid ultrasound was performed by two of us (F. Barker Davis and S. Hieronimus) who concerted and agreed before the study about thyroid volume measurement criteria using an En Visor scanner (Philips Medical System) equipped with a commercially available from 5 to 12 MHz linear transducer (50 mm length). Volume was calculated in mL for each lobe according to the formula 0.52 × height × width × thickness in centimeters. Total thyroid volume was the sum of each lobe’s volume, the isthmus was not taken into account in volume calculation.


## 2.2. Assays

Spot UIE was measured by mass spectrometry ICP/MS (Pasteur-Cerba Laboratory, Cergy Pontoise, France, detection threshold 15μg/L; intra- and interseries CV < 10%). Free T4 (fT4), free T3 (fT3), total T4 (TT4), TSH, βhCG, and anti-TPO and anti-Tg antibodies were measured by chemiluminescence (ADVIA Centaur, Siemens Healthcare Diagnostics, France). Tg was measured by immunoradiometric assay (Thyroglobulin IRMA, Cis bio International, Gif sur Yvette, France). Thyroxin binding globulin (TBG) and reverse T3 (rT3) were measured by radio-immunoassay (RIA): RIA-gnost TBG (Cis bio International, Gif sur Yvette, France) and RIA rT3 (Pasteur Cerba Laboratory, Cergy Pontoise, France). Reference ranges outside pregnancy, intra- and intercoefficients of variation were as the following: fT4 9–23 pmol/L (intra-assay coefficient of variation (CV) 2.31%; interassay CV 1.95%); fT3 3–7 pmol/L (intra-assay CV 2.35); TT4 during pregnancy 82.6–138 nmol/L (intra-assay CV 1.77%; interassay CV 2.9%); TSH 0.1–4 mUI/L (intra-assay CV 2.67%; interassay CV 3.97%); βhCG < 10 UI/L (intra-assay CV 2.8%; interassay CV 4.3%); TPO antibodies < 100 UI/mL (intra-assay CV 4.1%, interassay CV 8.0%); Tg antibodies < 60 UI/mL (intra-assay CV 5.5%; interassay CV 1.8%); Tg 5–50 ng/mL (intra-assay CV 2.4%; interassay CV 4.5%); rT3 0.14–0.54 nmol/L (intra-assay CV 8.54% interassay CV 6.21%); reference range for TBG for the first trimester 20.5±4.8 μg/mL (interassay CV 4.4%).


## 2.3. Statistics

Quantitative variables are expressed as means and standard deviation, medians, and range. Qualitative variables are expressed as counts and percentages. Student’st test or Mann-Whitney’s U test were used to compare continuous variables. Chi-2 test or Fisher’s exact test were used for categorical variables. The correlations between variables were determined using the Pearson’s test or Spearman’s rank test. The nonparametric Kruskal-Wallis test was used to examine associations between maternal smoking and thyroid function tests.Statistical analyses were performed using the software SAS version 9.1. Values were considered significant whenP<0.05. All tests were two-sided.


## 3. Results

### 3.1. Clinical Characteristics of the 110 Included Women

Their median age was 27.5 y (18–40), their body mass index (BMI) was 22.4 (16–45.3), with a weight at inclusion of 61.5 kg (43–128 kg), and they were nulliparous in 44.5%. 53% had never smoked, 18% were former smokers, and 28% were current smokers. 15% had a family history of thyroid disease; 82% were born in France (including 56% in our area). Thyroid ultrasound allowed the detection of 16 nodules (14.6%), including six women with nodules >1 cm. Global thyroid volume was 9.4 mL (4.5–17.9 mL); thus, no patient had thyroid hyperplasia or goiter.


### 3.2. UIE and Thyroid Tests (Table1)

Table 1
Ioduria and thyroid tests performed at 8 weeks of amenorrhea (5–12) in the 110 included women.
Median
Mean ± SD
Min
Max
Ioduriaμg/L
116
139 ± 98
<15
399
fT4 pmol/L
14.35
14.57 ± 1.65
12.0
19.16
TSH mUI/L
1.18
1.24 ± 0.58
0.13
2.47
fT3 pmol/L
5.0
5.1 ± 0.5
3.8
6.7
TT4 nmol/L
110.7
111.1 ± 23
50.7
167.4
TBGμg/mL
26.7
28.1 ± 7.2
12.8
50
Tg ng/mL
17.4
22.3 ± 17.2
1.3
100
βhCG UI/L
62724
65289 ± 47845
1025
220731
rT3 nmol/L
0.27
0.27 ± 0.07
0.13
0.51Median ioduria was 116μg/L. The repartition of the population according to WHO criteria during pregnancy (WHO) for iodine status (15) is shown in Figure 1: 1% (n=1) with severe ID <20 μg/L; 18% (n=17) with moderate iodine deficiency, UIE between 20 and 50 μg/L; 47% (n=45) with mild ID, UIE between 50 and 149 μg/L; 19% (n=18) with adequate iodine intake, UIE between 150–250 μg/L; 15% (n=14) with more than adequate iodine intake. With a threshold of UIE at 150 μg/L, 66% of pregnant women seen early were considered iodine deficient. There was no seasonal variation in UIE (data not shown). Women with ID based on UIE < 150 μg/L tended to have higher thyroid volumes (n=61, median 10 mL) compared to women with UIE between 150 and 250 μg/L (n=19, median 8.9 mL), while women with UIE > 250 mcg/L had intermediate volume (n=14, median 9.4 mL).Figure 1
Distribution of ioduria (UIE) in healthy euthyroid pregnant women. Solid black histograms represent women (n=63 of 95) with UIE reflecting ID according to the latest WHO guidelines (UIE < 150 μg/L).Table1 summarizes all thyroid tests. Among those women with normal thyroid tests, seven had a Tg > 50 ng/L (upper limit of normal for nonpregnant women). Those seven women had higher TSH (1.73 versus 1.15 mUI/L, P=0.04), less homogenous thyroid on ultrasound (four out of seven, versus nine out of 103, P<0.0001) and were more often smokers (five out of seven, versus 24 out of 103, P=0.0006). Last, women who later had a miscarriage (n=7) had lower βhCG (9930 versus 66704 UI/L, P=0.005) and lower TT4 (94.9 versus 111.6 pmol/L, P=0.04).


### 3.3. Correlations (Table2)

Table 2
Main significant correlations.
Ioduria
Negatively
Maternal age
r
=
-
0.2
P
=
0.05
Thyroid volume
r
=
-
0.22
P
=
0.03
Positively
βHCG
r
=
0.27
P
<
0.01
TSH
Negatively
fT4
r
=
-
0.27
P
<
0.005
rT3
r
=
-
0.24
P
=
0.01
βhCG
r
=
-
0.36
P
<
0.0001
Positively
Maternal weight
r
=
0.19
P
=
0.06
fT4
Negatively
Maternal weight
r
=
-
0.2
P
=
0.05
Positively
TT4
r
=
0.44
P
<
0.0001
rT3
r
=
0.44
P
<
0.0001
β
hCG
r
=
0.18
P
=
0.058
fT3
Positively
Tg
r
=
0.22
P
=
0.02
rT3
Negatively
Smoking
P
=
0.001
Positively
βhCG
r
=
0.4
P
<
0.0001
fT4
r
=
0.44
P
<
0.0001
TT4
r
=
0.5
P
<
0.0001
TBG
r
=
0.33
P
=
0.0005
Tg
Positively
fT3
r
=
0.22
P
=
0.02
Smoking
P
=
0.0001
βhCG
Negatively
TSH
r
=
-
0.36
P
<
0.0001
Positively
Ioduria
r
=
0.27
P
<
0.01
TT4
r
=
0.3
P
<
0.005
fT4
r
=
0.18
P
=
0.058
rT3
r
=
0.4
P
<
0.0001
TBG
r
=
0.40
P
<
0.0001
Thyroid volume
Negatively
Ioduria
r
=
-
0.22
P
=
0.05
Positively
Smoking
P
=
0.02UIE did not correlate with any of the thyroid tests. However, it correlated negatively with thyroid volume and maternal age, but not with parity nor gravidity. It correlated positively withβHCG.Thyroid tests correlated strongly with term (data not shown) and even more withβhCG: βhCG correlated negatively with TSH and positively with TT4, rT3, and TBG, and marginally with fT4. Maternal weight tended to correlate negatively with fT4 and positively with TSH. There was no correlation of thyroid volume with thyroid tests, including Tg (data not shown).Maternal smoking was associated with higher thyroid volume (smokers 10.6 mL versus 9.3 mL in nonsmokers,P=0.04) and higher Tg (smokers 30.6 versus nonsmokers 14.8 ng/mL, P=0.0005), and with lower rT3 (smokers 0.2 versus nonsmokers 0.3 nmol/L, P=0.01).


## 3.1. Clinical Characteristics of the 110 Included Women

Their median age was 27.5 y (18–40), their body mass index (BMI) was 22.4 (16–45.3), with a weight at inclusion of 61.5 kg (43–128 kg), and they were nulliparous in 44.5%. 53% had never smoked, 18% were former smokers, and 28% were current smokers. 15% had a family history of thyroid disease; 82% were born in France (including 56% in our area). Thyroid ultrasound allowed the detection of 16 nodules (14.6%), including six women with nodules >1 cm. Global thyroid volume was 9.4 mL (4.5–17.9 mL); thus, no patient had thyroid hyperplasia or goiter.


## 3.2. UIE and Thyroid Tests (Table1)

Table 1
Ioduria and thyroid tests performed at 8 weeks of amenorrhea (5–12) in the 110 included women.
Median
Mean ± SD
Min
Max
Ioduriaμg/L
116
139 ± 98
<15
399
fT4 pmol/L
14.35
14.57 ± 1.65
12.0
19.16
TSH mUI/L
1.18
1.24 ± 0.58
0.13
2.47
fT3 pmol/L
5.0
5.1 ± 0.5
3.8
6.7
TT4 nmol/L
110.7
111.1 ± 23
50.7
167.4
TBGμg/mL
26.7
28.1 ± 7.2
12.8
50
Tg ng/mL
17.4
22.3 ± 17.2
1.3
100
βhCG UI/L
62724
65289 ± 47845
1025
220731
rT3 nmol/L
0.27
0.27 ± 0.07
0.13
0.51Median ioduria was 116μg/L. The repartition of the population according to WHO criteria during pregnancy (WHO) for iodine status (15) is shown in Figure 1: 1% (n=1) with severe ID <20 μg/L; 18% (n=17) with moderate iodine deficiency, UIE between 20 and 50 μg/L; 47% (n=45) with mild ID, UIE between 50 and 149 μg/L; 19% (n=18) with adequate iodine intake, UIE between 150–250 μg/L; 15% (n=14) with more than adequate iodine intake. With a threshold of UIE at 150 μg/L, 66% of pregnant women seen early were considered iodine deficient. There was no seasonal variation in UIE (data not shown). Women with ID based on UIE < 150 μg/L tended to have higher thyroid volumes (n=61, median 10 mL) compared to women with UIE between 150 and 250 μg/L (n=19, median 8.9 mL), while women with UIE > 250 mcg/L had intermediate volume (n=14, median 9.4 mL).Figure 1
Distribution of ioduria (UIE) in healthy euthyroid pregnant women. Solid black histograms represent women (n=63 of 95) with UIE reflecting ID according to the latest WHO guidelines (UIE < 150 μg/L).Table1 summarizes all thyroid tests. Among those women with normal thyroid tests, seven had a Tg > 50 ng/L (upper limit of normal for nonpregnant women). Those seven women had higher TSH (1.73 versus 1.15 mUI/L, P=0.04), less homogenous thyroid on ultrasound (four out of seven, versus nine out of 103, P<0.0001) and were more often smokers (five out of seven, versus 24 out of 103, P=0.0006). Last, women who later had a miscarriage (n=7) had lower βhCG (9930 versus 66704 UI/L, P=0.005) and lower TT4 (94.9 versus 111.6 pmol/L, P=0.04).


## 3.3. Correlations (Table2)

Table 2
Main significant correlations.
Ioduria
Negatively
Maternal age
r
=
-
0.2
P
=
0.05
Thyroid volume
r
=
-
0.22
P
=
0.03
Positively
βHCG
r
=
0.27
P
<
0.01
TSH
Negatively
fT4
r
=
-
0.27
P
<
0.005
rT3
r
=
-
0.24
P
=
0.01
βhCG
r
=
-
0.36
P
<
0.0001
Positively
Maternal weight
r
=
0.19
P
=
0.06
fT4
Negatively
Maternal weight
r
=
-
0.2
P
=
0.05
Positively
TT4
r
=
0.44
P
<
0.0001
rT3
r
=
0.44
P
<
0.0001
β
hCG
r
=
0.18
P
=
0.058
fT3
Positively
Tg
r
=
0.22
P
=
0.02
rT3
Negatively
Smoking
P
=
0.001
Positively
βhCG
r
=
0.4
P
<
0.0001
fT4
r
=
0.44
P
<
0.0001
TT4
r
=
0.5
P
<
0.0001
TBG
r
=
0.33
P
=
0.0005
Tg
Positively
fT3
r
=
0.22
P
=
0.02
Smoking
P
=
0.0001
βhCG
Negatively
TSH
r
=
-
0.36
P
<
0.0001
Positively
Ioduria
r
=
0.27
P
<
0.01
TT4
r
=
0.3
P
<
0.005
fT4
r
=
0.18
P
=
0.058
rT3
r
=
0.4
P
<
0.0001
TBG
r
=
0.40
P
<
0.0001
Thyroid volume
Negatively
Ioduria
r
=
-
0.22
P
=
0.05
Positively
Smoking
P
=
0.02UIE did not correlate with any of the thyroid tests. However, it correlated negatively with thyroid volume and maternal age, but not with parity nor gravidity. It correlated positively withβHCG.Thyroid tests correlated strongly with term (data not shown) and even more withβhCG: βhCG correlated negatively with TSH and positively with TT4, rT3, and TBG, and marginally with fT4. Maternal weight tended to correlate negatively with fT4 and positively with TSH. There was no correlation of thyroid volume with thyroid tests, including Tg (data not shown).Maternal smoking was associated with higher thyroid volume (smokers 10.6 mL versus 9.3 mL in nonsmokers,P=0.04) and higher Tg (smokers 30.6 versus nonsmokers 14.8 ng/mL, P=0.0005), and with lower rT3 (smokers 0.2 versus nonsmokers 0.3 nmol/L, P=0.01).


## 4. Discussion

We have selected women with strictly normal thyroid function, in choosing stringent criteria (above 10th percentile of our trimester specific reference range for fT4 and <2.5 mUI/L for TSH). There was no goiter nor thyroid hypertrophy as assessed by ultrasound. Thyroid volume in our population was smaller than the volume observed by Glinoer et al. (14.3 mL) in his population with “stimulated” thyroid [10]. The rate of thyroid incidentaloma was similar to the rate observed in the general population [15].The median UIE in our population with no iodine supplementation was 116μg/L, which is below the currently recommended threshold in pregnancy (150 μg/L), in the range of mild iodine deficiency [16]. While spot ioduria is useless to establish the diagnosis of ID at an individual level, given its variation from day to day [1], so far it remains the gold standard at the population level [17]. There is a wide range of published UIE values in pregnancy, depending in part on national public health policies to tackle iodine deficiency. Another important variation factor is gestational age, with a steady decline from the first trimester to the end of pregnancy [18]. Indeed, the apparent better iodine status in early pregnancy may be instead due to the increase of glomerular filtration during first trimester causing an increased UIE [19] and, thus, an increased loss of iodine. Two previous studies in France, including one from our Department, have shown lower UIE values at the end of pregnancy: 54 μg/L [20] and 64 μg/L [2]. When focusing on the first trimester, in other Mediterranean countries, figures were similar or lower in Spain 95 μg/L [21] and 125 μg/L [22], and in Italy (115 in long-term supplementation versus 63 μg/L in short-term supplementation [23]). However, UIE was higher in Switzerland (267 μg/L) where an active program of supplementation exists [24, 25]. On the other hand, in Belgium, UIE was very low (36 μg/L) in a selected population of women with excessive thyroid stimulation [10]. Based on UIE, in our study of selected women with normal thyroid function in early pregnancy, ID was present in 66% of cases, using a threshold of 150 μg/L. This prevalence was similar to those many studies worldwide performed at the same gestational age, except for Brander in Switzerland [24].UIE did not correlate with any parameters of maternal thyroid function at this stage of pregnancy in our selected healthy population. We had already reported this lack of correlation in our previous study performed during the third trimester [2]. This has also been reported by Fuse et al. [26] in a large population in an area of sufficient iodine intake, though women with excessive intake (UIE > 1 mg/L) had higher TSH [26]. In a population with moderate-to-severe iodine deficiency, it is usually reported a relative hypothyroxinemia, with or without elevation of TSH, particularly in women with predisposition to thyroid disease [8]. On the other hand, Orito et al. had shown in early pregnancy a positive correlation of UIE with TSH and a negative correlation with fT4 and fT3 in an area of excess iodine intake [27]. This suggests a U-shape curve with higher TSH observed in case of iodine deficiency and in areas of iodine excess. To some degree, this is true with thyroid volume as well. UIE in our patients correlated negatively with thyroid volume as measured by ultrasound, the smaller volume of thyroid being noted in women with adequate iodine intake. An inverse relationship between UIE and thyroid volume has also been well documented in schoolchildren in Europe, including France [28].In contrast with UIE,βhCG correlated strongly with thyroid tests. As expected, we found a negative correlation of βhCG and TSH, reflecting the classical TSH-like activity of βhCG [8]. βHCG correlated positively with all the tested parameters, including rT3, except for fT3. Thus, βhCG appears as the main driver of thyroid function at this stage of pregnancy, as also suggested by Haddow [29]. We report here a correlation of βHCG with rT3. Interestingly, Asakura et al. have reported a correlation of rT3 with the severity of hyperemesis gravidarum [30], a condition generally associated with high βhCG levels. This could suggest a shift in deiodinase activity in that condition.Of note, we report a strong correlation ofβhCG with UIE. One physiological explanation could be that βhCG stimulates relaxin secretion by the corpus luteum, which plays an important physiologic role in the maternal renal adaptation to pregnancy [31]. We speculate that this could contribute to gestational increased UIE during the first trimester.Maternal smoking is recognized as a stress on the thyroid [32]. The higher thyroid volume and higher thyroglobulin levels we report here in smokers illustrate the deleterious impact of tobacco on the thyroid. We found no correlation between maternal smoking and UIE, though median UIE was slightly lower in smokers (data not shown). Importantly, there was no correlation as well between Tg and UIE. This shows that Tg is more likely a marker of maternal smoking than iodine deficiency at this stage of pregnancy in an area of mild iodine deficiency. However, later in pregnancy, maternal smoking has a significant impact on CB Tg only, but not on maternal Tg [33]. The strong negative correlation of smoking with rT3 has not been reported before and could suggest an effect of tobacco on deiodinase activity. In contrast, we found no correlation of maternal smoking with other thyroid parameters. Shields et al. had found correlations during the first trimester with TSH (lower), and fT3 (higher), and no correlation with fT4 [34]. There was no information on Tg nor thyroid volume, nor rT3. On the other hand, Pearce et al. found that fT4 was lower in women smoking during pregnancy. They did not find association of TSH with smoking or the use of iodine containing vitamins [35]. The impact of other toxics, such as known endocrine disruptors (e.g., PCBs) could also play a role in pregnancy [36, 37].


## 5. Conclusion

In pregnant women of our area selected for a strictly normal thyroid function, ID is present in two-third of women during the 1st trimester, though usually mild. The absence of correlation between UIE and thyroid tests at that stage of pregnancy contrasts with the impact ofβHCG that appears as the main driver of maternal thyroid function in early pregnancy, possibly overriding ID. In addition, our study illustrates the impact of maternal smoking on thyroid volume, Tg, and rT3.



---

*Source: 168764-2012-11-28.xml*